SEC Form 4 · accession 0001562180-19-000371
Intersect ENT, Inc. · XENT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gwen R. Carscadden
Officer — Chief People Officer
Period of report
Jan 16, 2019
Accepted (ET)
Jan 18, 2019 · 5:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001271214
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 16, 2019 | A | 4,500 | $0.00 | A | 12,179 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $28.58 | Jan 16, 2019 | A | 21,000 | A | — | Jan 15, 2029 | Common Stock | 21,000 | 21,000 | D |
Explanation of responses
- F1Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in three equal annual installments commencing on January 1, 2019.
- F2Includes 9,533 Restricted Stock Units.
- F3The vesting commencement date of the option is January 1, 2019. 1/8th of the shares subject to the option shall vest on July 1, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months.